Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier.
Efflux pumps, P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), and breast cancer resistance protein (BCRP) have been shown to extrude HIV protease inhibitors from cells. These transporters are present on many barrier sites such as the blood-brain barrier (BBB) and on many circulating cells such as lymphocytes, and could reduce protease inhibitor concentration in sanctuary or HIV-1 target sites. This study compares the potential of the antiretroviral drug atazanavir to modulate P-gp and MRP expression and function in total lymphocytes and in human fetal brain endothelial cells (HBMECs). We address the question of atazanavir transport across the human BBB. Following incubation with atazanavir, P-gp and MRP1 expression was determined by direct immunofluorescence. Transporter function was assessed by measuring fluorescent dye efflux, either with or without specific inhibitors. Atazanavir substrate properties were determined by transport quantification through a validated in vitro human BBB model. Our results show that in contrast to HBMECs, in lymphocytes, atazanavir has no effect on MRP1 and P-gp expression. However, there were overall changes in P-gp function increasing its activity in lymphocytes and HBMECs. Using the in vitro human BBB model, we confirm the interaction of atazanavir with P-gp, MRPs, and BCRP in preventing its passage across this barrier and thus its entry into the central nervous system.
Bousquet
Laurence
L
CEA, iBiTec-S, Service de Pharmacologie et d'Immunoanalyse, Gif-sur-Yvette, France.
Roucairol
Camille
C
Hembury
Alexandra
A
Nevers
Marie-Claire
MC
Creminon
Christophe
C
Farinotti
Robert
R
Mabondzo
Aloïse
A
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism; D018528:ATP-Binding Cassette Transporters / Q000096:biosynthesis* / Q000187:drug effects*; D000069446:Atazanavir Sulfate; D001812:Blood-Brain Barrier / Q000378:metabolism; D001921:Brain; D002478:Cells, Cultured; D042783:Endothelial Cells / Q000187:drug effects*; D005456:Fluorescent Dyes / Q000378:metabolism; D020869:Gene Expression Profiling; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics* / Q000494:pharmacology; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D008856:Microscopy, Fluorescence; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000378:metabolism; D009842:Oligopeptides / Q000493:pharmacokinetics* / Q000494:pharmacology; D011725:Pyridines / Q000493:pharmacokinetics* / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D018528:ATP-Binding Cassette Transporters; D000069446:Atazanavir Sulfate; D005456:Fluorescent Dyes; D017320:HIV Protease Inhibitors; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D009842:Oligopeptides; D011725:Pyridines